Myomo Leads The Pack Of 3 Promising Penny Stocks

In the last week, the market has stayed flat, but it is up 18% over the past year with earnings forecast to grow by 17% annually. For those looking to invest in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer surprising value. Typically representing affordable entry points into potentially high-growth sectors, these stocks can shine when backed by strong financials and solid fundamentals.

We're going to check out a few of the best picks from our screener tool.

Myomo (MYO)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Myomo, Inc. is a wearable medical robotics company that designs, develops, and produces myoelectric orthotics for individuals with neuromuscular disorders across the United States, Germany, and internationally; it has a market cap of $63.37 million.

Operations: The company generates its revenue from the Medical Products segment, amounting to $43.26 million.

Market Cap: $63.37M

Myomo, Inc. has demonstrated revenue growth with second-quarter sales reaching US$11.7 million, up from US$9.65 million the previous year, and has raised its full-year revenue guidance to between US$45 million and US$47 million for 2026. Despite being unprofitable with a negative return on equity of -248.87%, Myomo's short-term assets exceed both its short- and long-term liabilities, indicating financial stability in the near term. The company’s management is experienced, although it faces high share price volatility and increased debt levels over recent years, challenging its path to profitability within three years.

• Get an in-depth perspective on Myomo's performance by reading our balance sheet health report here.
• Explore Myomo's analyst forecasts in our growth report.

Xtant Medical Holdings (XTNT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Xtant Medical Holdings, Inc. offers regenerative medicine products and medical devices for orthopedic and neurological surgeons both in the United States and internationally, with a market cap of $53.87 million.

Operations: The company generates revenue of $109.53 million from its operations focused on the development, manufacture, and marketing of orthopedic medical products and devices.

Market Cap: $53.87M

Xtant Medical Holdings, Inc. has recently partnered with BioHorizons to distribute its allogeneic growth factor technology, Prolifica™, expanding its market reach in the dental and oral-maxillofacial sectors. Despite this strategic move, Xtant reported a significant decline in second-quarter revenue to US$23.03 million from US$35.41 million a year ago, resulting in a net loss of US$9.41 million compared to prior net income. The company lowered its full-year revenue guidance amid ongoing unprofitability and negative return on equity of -27.83%. However, it maintains financial stability with short-term assets exceeding liabilities and no significant shareholder dilution recently observed.

• Click here to discover the nuances of Xtant Medical Holdings with our detailed analytical financial health report.
• Evaluate Xtant Medical Holdings' prospects by accessing our earnings growth report.

CS Disco (LAW)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CS Disco, Inc. offers cloud-native and AI-powered legal solutions for various legal processes such as ediscovery and case management, with a market cap of $281.75 million.

Operations: The company's revenue is generated entirely from the sale and support of its legal product offerings, totaling $167.12 million.

Market Cap: $281.75M

CS Disco, Inc. has been actively enhancing its AI-powered legal solutions, recently launching significant features like the Auto Review and Advanced Research tools to streamline legal processes. Despite these innovations, the company remains unprofitable with a net loss of US$8.66 million in Q2 2026, although this is an improvement from the previous year. Its financial position shows stability with no debt and sufficient cash runway for over three years. However, it faces challenges such as being dropped from several Russell 2000 indices and experiencing insider selling in recent months.

• Click to explore a detailed breakdown of our findings in CS Disco's financial health report.
• Learn about CS Disco's future growth trajectory here.

Where To Now?

• Access the full spectrum of 312 US Penny Stocks by clicking on this link.
• Looking For Alternative Opportunities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com